Markets
News
Analysis
User
24/7
Economic Calendar
Education
Data
- Names
- Latest
- Prev












Signal Accounts for Members
All Signal Accounts
All Contests



China, Mainland M0 Money Supply YoY (Nov)A:--
F: --
P: --
China, Mainland M1 Money Supply YoY (Nov)A:--
F: --
P: --
India CPI YoY (Nov)A:--
F: --
P: --
India Deposit Gowth YoYA:--
F: --
P: --
Brazil Services Growth YoY (Oct)A:--
F: --
P: --
Mexico Industrial Output YoY (Oct)A:--
F: --
P: --
Russia Trade Balance (Oct)A:--
F: --
P: --
Philadelphia Fed President Henry Paulson delivers a speech
Canada Building Permits MoM (SA) (Oct)A:--
F: --
P: --
Canada Wholesale Sales YoY (Oct)A:--
F: --
P: --
Canada Wholesale Inventory MoM (Oct)A:--
F: --
P: --
Canada Wholesale Inventory YoY (Oct)A:--
F: --
P: --
Canada Wholesale Sales MoM (SA) (Oct)A:--
F: --
P: --
Germany Current Account (Not SA) (Oct)A:--
F: --
P: --
U.S. Weekly Total Rig CountA:--
F: --
P: --
U.S. Weekly Total Oil Rig CountA:--
F: --
P: --
Japan Tankan Small Manufacturing Outlook Index (Q4)A:--
F: --
P: --
Japan Tankan Large Non-Manufacturing Diffusion Index (Q4)A:--
F: --
P: --
Japan Tankan Large Non-Manufacturing Outlook Index (Q4)A:--
F: --
P: --
Japan Tankan Large Manufacturing Outlook Index (Q4)A:--
F: --
P: --
Japan Tankan Small Manufacturing Diffusion Index (Q4)A:--
F: --
P: --
Japan Tankan Large Manufacturing Diffusion Index (Q4)A:--
F: --
P: --
Japan Tankan Large-Enterprise Capital Expenditure YoY (Q4)A:--
F: --
P: --
U.K. Rightmove House Price Index YoY (Dec)A:--
F: --
P: --
China, Mainland Industrial Output YoY (YTD) (Nov)A:--
F: --
P: --
China, Mainland Urban Area Unemployment Rate (Nov)A:--
F: --
P: --
Saudi Arabia CPI YoY (Nov)A:--
F: --
P: --
Euro Zone Industrial Output YoY (Oct)A:--
F: --
P: --
Euro Zone Industrial Output MoM (Oct)A:--
F: --
P: --
Canada Existing Home Sales MoM (Nov)A:--
F: --
P: --
Euro Zone Total Reserve Assets (Nov)--
F: --
P: --
U.K. Inflation Rate Expectations--
F: --
P: --
Canada National Economic Confidence Index--
F: --
P: --
Canada New Housing Starts (Nov)--
F: --
P: --
U.S. NY Fed Manufacturing Employment Index (Dec)--
F: --
P: --
U.S. NY Fed Manufacturing Index (Dec)--
F: --
P: --
Canada Core CPI YoY (Nov)--
F: --
P: --
Canada Manufacturing Unfilled Orders MoM (Oct)--
F: --
P: --
U.S. NY Fed Manufacturing Prices Received Index (Dec)--
F: --
P: --
U.S. NY Fed Manufacturing New Orders Index (Dec)--
F: --
P: --
Canada Manufacturing New Orders MoM (Oct)--
F: --
P: --
Canada Core CPI MoM (Nov)--
F: --
P: --
Canada Trimmed CPI YoY (SA) (Nov)--
F: --
P: --
Canada Manufacturing Inventory MoM (Oct)--
F: --
P: --
Canada CPI YoY (Nov)--
F: --
P: --
Canada CPI MoM (Nov)--
F: --
P: --
Canada CPI YoY (SA) (Nov)--
F: --
P: --
Canada Core CPI MoM (SA) (Nov)--
F: --
P: --
Canada CPI MoM (SA) (Nov)--
F: --
P: --
Federal Reserve Board Governor Milan delivered a speech
U.S. NAHB Housing Market Index (Dec)--
F: --
P: --
Australia Composite PMI Prelim (Dec)--
F: --
P: --
Australia Services PMI Prelim (Dec)--
F: --
P: --
Australia Manufacturing PMI Prelim (Dec)--
F: --
P: --
Japan Manufacturing PMI Prelim (SA) (Dec)--
F: --
P: --
U.K. 3-Month ILO Employment Change (Oct)--
F: --
P: --
U.K. Unemployment Claimant Count (Nov)--
F: --
P: --
U.K. Unemployment Rate (Nov)--
F: --
P: --
U.K. 3-Month ILO Unemployment Rate (Oct)--
F: --
P: --
U.K. Average Weekly Earnings (3-Month Average, Including Bonuses) YoY (Oct)--
F: --
P: --
U.K. Average Weekly Earnings (3-Month Average, Excluding Bonuses) YoY (Oct)--
F: --
P: --


No matching data
Latest Views
Latest Views
Trending Topics
Top Columnists
Latest Update
White Label
Data API
Web Plug-ins
Affiliate Program
View All

No data
A major regulatory decision for reproxalap in dry eye disease is expected in December, with a lucrative AbbVie partnership pending approval. The drug's rapid onset and anti-redness features set it apart, and future plans include expanding into allergic conjunctivitis and other indications.
A major regulatory decision for Reproxalap in dry eye disease is expected in December, with a lucrative AbbVie partnership pending approval. The drug’s rapid onset and anti-redness features set it apart, and late-stage data support expansion into allergic conjunctivitis.
A major FDA decision for a dry eye therapy is expected in December, with strong clinical data and commercial plans in place, including a significant partnership with AbbVie. The pipeline includes late-stage and preclinical programs targeting ocular, dermatological, and neurological diseases.
RASP modulation platform is expanding into CNS and immune-mediated diseases, with ADX-248 showing strong preclinical efficacy and reproxalap advancing toward potential FDA approval. Financial runway extends into 2027, and key regulatory and manufacturing milestones have been met.
Based on Aldeyra Therapeutics, Inc. [ALDX] R&D Day 2025 Audio Transcript — Nov. 13 2025
The RASP platform is expanding into CNS diseases, with ADX248 showing strong preclinical efficacy and reproxalap advancing toward potential FDA approval for dry eye disease. Manufacturing and regulatory milestones have been met, and the company is well-funded for upcoming trials.
Based on Aldeyra Therapeutics, Inc. [ALDX] R&D Day 2025 Audio Transcript — Nov. 13 2025
A broad immunology pipeline is advancing, highlighted by reproxalap's NDA review for dry eye disease and a major AbbVie partnership. Multiple clinical and preclinical programs are progressing, with strong cash reserves supporting operations into 2027.
Original document: Aldeyra Therapeutics, Inc. [ALDX] Slides Release — Nov. 13 2025
White Label
Data API
Web Plug-ins
Poster Maker
Affiliate Program
The risk of loss in trading financial instruments such as stocks, FX, commodities, futures, bonds, ETFs and crypto can be substantial. You may sustain a total loss of the funds that you deposit with your broker. Therefore, you should carefully consider whether such trading is suitable for you in light of your circumstances and financial resources.
No decision to invest should be made without thoroughly conducting due diligence by yourself or consulting with your financial advisors. Our web content might not suit you since we don't know your financial conditions and investment needs. Our financial information might have latency or contain inaccuracy, so you should be fully responsible for any of your trading and investment decisions. The company will not be responsible for your capital loss.
Without getting permission from the website, you are not allowed to copy the website's graphics, texts, or trademarks. Intellectual property rights in the content or data incorporated into this website belong to its providers and exchange merchants.
Not Logged In
Log in to access more features

FastBull Membership
Not yet
Purchase
Log In
Sign Up